Know Labs Stock Price, News & Analysis

Know Labs, Inc. (NYSE American: KNW) has provided an update on its strategic partnerships to advance the FDA clearance for its innovative non-invasive glucose monitoring devices. The company collaborates with experts in data science, regulatory affairs, and product design, aiming to transform patient care. Key partners include Igor Institute, Bould Design, Edge Impulse, and NOVUS Management Group, who contribute expertise in areas like engineering and algorithm development. Know Labs plans to validate its Bio-RFID technology for accurate glucose measurement in 2023 while continuing to build its advisory board. The non-invasive glucose monitor could revolutionize diabetes management.

Know Labs, Inc. (NYSE American: KNW) announced executive leadership changes aimed at accelerating the development of its Bio-RFID™ technology. Effective immediately, Ron Erickson, the founder, has been appointed CEO, bringing nearly 20 years of experience. Masanori King Takee is now Chief Technology Officer, focusing on software and data science to refine Bio-RFID algorithms. Jessica English joins as Chief Marketing Officer to lead marketing efforts, while Leo Trautwein is promoted to Chief Commercial Officer. The company aims to validate its technology through data science and partnerships for clinical trials in 2023.

Know Labs, Inc. (NYSE American: KNW) has appointed founder Ron Erickson as the new CEO, succeeding Phil Bosua, who transitions to a technology advisor role. Erickson, with nearly 20 years at Know Labs and over 30 years in leadership roles, emphasized the importance of accelerating product development for the Bio-RFID technology, aimed at non-invasive glucose monitoring. The company is focused on FDA clearance and enhancing its product development team in 2023. The Board supports this leadership change, highlighting an aggressive strategy to transform medical diagnostics and enhance shareholder value.

Know Labs, Inc. (AMEX: KNW) has been granted a new foundational patent for its Bio-RFID diagnostic technology, establishing a superior benchmark range of clinical accuracy (MARD) for glucose monitoring. This patent extends its intellectual property portfolio to nearly 90 patents, solidifying its position in non-invasive glucose monitoring. The patented MARD range of 5.0% to 9.9% sets it apart from existing glucose monitoring devices. Know Labs aims to become a reference standard in glucose testing, with plans to continue its FDA clearance process for its non-invasive glucose monitoring device.

Know Labs, Inc. (KNW) reported financial results for the fiscal year ending September 30, 2022, highlighting consolidated revenues of $4.360 million. The R&D expenses surged to $5.386 million from the prior year’s $3.970 million, driven by staffing and technological advancements. The net loss for the year stood at $20.071 million, a decrease from $25.360 million in 2021. Cash and equivalents remained stable at $12.594 million. Current assets exceeded current liabilities, indicating a healthy current ratio of 3.61 compared to 1.17 in 2021.

Know Labs, Inc. (AMEX:KNW) addressed recent false claims from a research firm linked to short-selling. The company remains confident in its Bio-RFID™ technology for non-invasive glucose monitoring, aiming for FDA clearance. Founder Ron Erickson criticized the motives of those spreading misinformation for financial gain, asserting the uniqueness of their technology in the diagnostics field. Know Labs is set to report its Q4 and fiscal year 2022 results today, following a recent presentation to institutional investors.

Know Labs, Inc. (AMEX: KNW) will host a webcast on December 20, 2022, at 1:30 PM PT to review updates and results for its fiscal year ending September 30, 2022. The public can access the live audio webcast through the company's investor relations website. Know Labs focuses on developing non-invasive medical diagnostic technology, including a patented Bio-RFID™ technology for identifying analytes without invasive tests. The first application will be a non-invasive glucose monitor, pending FDA clearance.

Know Labs, Inc. (NYSE AMERICAN: KNW) will present at the Bernstein CGM Disruptors Conference on November 18, 2022. The company will update its Bio-RFID technology, aimed at non-invasive glucose monitoring. Bio-RFID uses radio-frequency spectroscopy to detect analytes in the bloodstream, with the first application being a glucose monitor that provides real-time blood glucose levels. This product requires FDA approval before market introduction. Know Labs focuses on integrating its technology into wearable devices for better health monitoring.

Know Labs, Inc. (KNW) has successfully completed its underwritten public offering, closing on 4,140,000 shares of Common Stock at $2.00 per share, generating approximately $8.28 million in gross proceeds. The offering included the underwriter’s option for an additional 540,000 shares. Trading for KNW stock commenced on the NYSE American on September 16, 2022. Boustead Securities, LLC served as the sole underwriter for the transaction.